FDA Approval Sought for Lurbinectedin in Small Cell Lung Cancer
A new drug application has been submitted to the FDA seeking an accelerated approval for lurbinectedin for use as a second-line treatment for patients with small cell lung cancer.
Related Articles
Fertility and Toxicity Considerations Factor into TNBC Management
Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Renowned breast cancer physician-scientist Hope S. Rugo, M.D., to lead City of Hope’s Women’s Cancers Program
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients
China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors
China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer
Nataliya Mar, MD, discusses clinical considerations when selecting between the wide range of androgen receptor pathway inhibitors in prostate cancer.
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma
Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.
Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD
A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.